Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.

Piubello A, Souleymane MB, Hassane-Harouna S, Yacouba A, Lempens P, Assao-Neino MM, Maman-Lawan I, Attaher S, Moustapha B, Soumana A, Gagara-Issoufou A, Ortuño-Gutiérrez N, Roggi A, Gumusboga M, Hamidou-Harouna Z, Dockx J, Mamadou S, de Jong BC, Decroo T, Van Deun A.

Respir Med. 2020 Jan;161:105844. doi: 10.1016/j.rmed.2019.105844. Epub 2019 Nov 23.

PMID:
32056722
2.

Tuberculosis treatment: one-shot approach or cascade of regimens?

Decroo T, de Jong BC, Piubello A, Lynen L, Van Deun A.

Lancet Respir Med. 2020 Feb;8(2):e4-e5. doi: 10.1016/S2213-2600(19)30473-4. No abstract available.

PMID:
32035067
3.

MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network.

Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, Muñoz Torrico M, Duarte R, Alffenaar JW, Schaaf HS, Marais BJ, Cirillo DM, Alagna R, Rendon A, Pontali E, Piubello A, Figueroa J, Ferlazzo G, García-Basteiro A, Centis R, Visca D, D'Ambrosio L, Sotgiu G; members of the Global Tuberculosis Network.

Int J Infect Dis. 2020 Feb 4. pii: S1201-9712(20)30045-X. doi: 10.1016/j.ijid.2020.01.042. [Epub ahead of print]

4.

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence.

Trébucq A, Decroo T, Van Deun A, Piubello A, Chiang CY, Koura KG, Schwoebel V.

J Clin Med. 2019 Dec 25;9(1). pii: E55. doi: 10.3390/jcm9010055. Review.

5.

Standardised shorter regimens versus individualised longer regimens for multidrug-resistant TB.

Abidi S, Achar J, Neino MMA, Bang D, Benedetti A, Brode S, Campbell JR, Casas E, Conradie F, Dravniece G, du Cros P, Falzon D, Jaramillo E, Kuaban C, Lan Z, Lange C, Li PZ, Makhmudova M, Maug AKJ, Menzies D, Migliori GB, Miller A, Myrzaliev B, Ndjeka N, Noeske J, Parpieva N, Piubello A, Schwoebel V, Sikhondze W, Singla R, Souleymane MB, Trébucq A, Van Deun A, Viney K, Weyer K, Zhang BJ, Khan FA.

Eur Respir J. 2019 Dec 20. pii: 1901467. doi: 10.1183/13993003.01467-2019. [Epub ahead of print]

PMID:
31862767
6.

World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.

Van Deun A, Decroo T, Tahseen S, Trébucq A, Schwoebel V, Ortuno-Gutierrez N, de Jong BC, Rieder HL, Piubello A, Chiang CY.

Int J Antimicrob Agents. 2020 Jan;55(1):105822. doi: 10.1016/j.ijantimicag.2019.10.003. Epub 2019 Oct 15.

PMID:
31626907
7.

Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.

Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, Aung KJM, Rieder HL.

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):965-971. doi: 10.5588/ijtld.19.0053.

PMID:
31615602
8.

The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.

Caminero JA, García-Basteiro AL, Rendon A, Piubello A, Pontali E, Migliori GB.

Eur Respir J. 2019 Oct 10;54(4). pii: 1901272. doi: 10.1183/13993003.01272-2019. Print 2019 Oct. No abstract available.

PMID:
31601719
9.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz-Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Dec 19;54(6). pii: 1901522. doi: 10.1183/13993003.01522-2019. Print 2019 Dec.

PMID:
31601711
10.

Multidrug-resistant tuberculosis.

Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL.

Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. No abstract available. Erratum in: Lancet. 2019 Aug 17;394(10198):564.

PMID:
31354138
11.

Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger.

Harouna SH, Ortuno-Gutierrez N, Souleymane MB, Kizito W, Morou S, Boukary I, Zolfo M, Benedetti G, Piubello A.

Int J Tuberc Lung Dis. 2019 May 1;23(5):625-630. doi: 10.5588/ijtld.17.0871.

PMID:
31097073
12.

Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.

Schwoebel V, Chiang CY, Trébucq A, Piubello A, Aït-Khaled N, Koura KG, Heldal E, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2019 May 1;23(5):619-624. doi: 10.5588/ijtld.18.0798. Erratum in: Int J Tuberc Lung Dis. 2019 Jul 1;23(7):876.

PMID:
31097072
13.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

14.

Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.

Harries AD, Schwoebel V, Monedero-Recuero I, Aung TK, Chadha S, Chiang CY, Conradie F, Dongo JP, Heldal E, Jensen P, Nyengele JPK, Koura KG, Kumar AMV, Lin Y, Mlilo N, Nakanwagi-Mukwaya A, Ncube RT, Nyinoburyo R, Oo NL, Patel LN, Piubello A, Rusen ID, Sanda T, Satyanarayana S, Syed I, Thu AS, Tonsing J, Trébucq A, Zamora V, Zishiri C, Hinderaker SG, Aït-Khaled N, Roggi A, Caminero Luna J, Graham SM, Dlodlo RA, Fujiwara PI.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):241-251. doi: 10.5588/ijtld.18.0207.

PMID:
30808459
15.

QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment.

Monedero-Recuero I, Hernando-Marrupe L, Sánchez-Montalvá A, Cox V, Tommasi M, Furin J, Chiang CY, Quelapio M, Koura KG, Trébucq A, Padanilam X, Dravniece G, Piubello A.

Int J Tuberc Lung Dis. 2018 Oct 26. doi: 10.5588/ijtld.18.0423. [Epub ahead of print]

PMID:
30366516
16.

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.

Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660. Review.

PMID:
29471899
17.

Should gatifloxacin be included in the model list of essential medicines?

Chiang CY, Trébucq A, Piubello A, Rieder HL, Van Deun A.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702329. doi: 10.1183/13993003.02329-2017. Print 2018 Feb. No abstract available.

18.

Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.

Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17.

PMID:
29149917
19.

Bedaquiline: how better to use it.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701670. doi: 10.1183/13993003.01670-2017. Print 2017 Nov. No abstract available.

20.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700648. doi: 10.1183/13993003.00648-2017. Print 2017 Jul. No abstract available.

21.

Shifts in Mycobacterial Populations and Emerging Drug-Resistance in West and Central Africa.

Gehre F, Ejo M, Fissette K, de Rijk P, Uwizeye C, Nduwamahoro E, Goovaerts O, Affolabi D, Gninafon M, Lingoupou FM, Barry MD, Sow O, Merle C, Olliaro P, Ba F, Sarr M, Piubello A, Noeske J, Antonio M, Rigouts L, de Jong BC.

PLoS One. 2014 Dec 10;9(12):e110393. doi: 10.1371/journal.pone.0110393. eCollection 2014.

22.

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.

Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94. doi: 10.5588/ijtld.13.0075.

PMID:
25216832
23.

Pulmonary tuberculosis in the Central Prison of Douala, Cameroon.

Noeske J, Kuaban C, Amougou G, Piubello A, Pouillot R.

East Afr Med J. 2006 Jan;83(1):25-30.

PMID:
16642747

Supplemental Content

Loading ...
Support Center